The last shall not be first: the ordered generation of progeny from stem cells

Towards predictive models of stem cell fate

Quantitative approaches are essential for the advancement of strategies to manipulate stem cells or their derivatives for therapeutic applications. Predictive models of stem cell systems would provide the means to pose and validate non-intuitive hypotheses and could thus serve as an important tool for discerning underlying regulatory mechanisms governing stem cell fate decisions. In this paper we review the development of computational models that attempt to describe mammalian adult and embryonic stem (ES) cell responses. Early stochastic models that relied exclusively on statistical distributions to describe the in vitro or in vivo output of stem cells are being revised to incorporate the contributions of exogenous and endogenous parameters on specific stem cell fate processes. Recent models utilize cell specific data (for example, cell-surface receptor distributions, transcription factor half-lives, cell-cycle status, etc.) to provide mechanistic descriptions that are consistent with biologically observed phenomena. Ultimately, the goal of these computational models is to, a priori, predict stem cell output given an initial set of conditions. Our efforts to develop a predictive model of ES cell fate are discussed. The quantitative studies presented in this review represent an important step in developing bioengineering approaches to characterize and predict stem cell behavior. Ongoing efforts to incorporate genetic and signaling network data into computational models should accelerate our understanding of fundamental principles governing stem cell fate decisions.

Long-Term Proliferation of Human Embryonic Stem Cell-Derived Neuroepithelial Cells Using Defined Adherent Culture Conditions

Research on the cell fate determination of embryonic stem cells is of enormous interest given the therapeutic potential in regenerative cell therapy. Human embryonic stem cells (hESCs) have the ability to renew themselves and differentiate into all three germ layers. The main focus of this study was to examine factors affecting derivation and further proliferation of multipotent neuroepithelial (NEP) cells from hESCs. hESCs cultured in serum-deprived defined medium developed distinct tube structures and could be isolated either by dissociation or adherently. Dissociated cells survived to form colonies of cells characterized as NEP when conditioned medium from human hepatocellular carcinoma HepG2 cell line (MEDII) was added. However, cells isolated adherently developed an enriched population of NEP cells independent of MEDII medium. Further characterization suggested that they were NEP cells because they had a similar phenotype profile to in vivo NEP cells and expression SOX1, SOX2, and SOX3 genes. They were positive for Nestin, a neural intermediate filament protein, and Musashi-1, a neural RNA-binding protein, but few cells expressed further differentiation markers, such as PSNCAM, A2B5, MAPII, GFAP, or O4, or other lineage markers, such as muscle actin, alpha fetoprotein, or the pluripotent marker Oct4. Further differentiation of these putative NEP cells gave rise to a mixed population of progenitors that included A2B5-positive and PSNCAM-positive cells and postmitotic neurons and astrocytes. To proliferate and culture these derived NEP cells, ideal conditions were obtained using neurobasal medium supplemented with B27 and basic fibroblast growth factor in 5% oxygen. NEP cells were continuously propagated for longer than 6 months without losing their multipotent cell characteristics and maintained a stable chromosome number.

Routes to regenerating islet cells: stem cells and other biological therapies for type 1 diabetes

New biological therapies for type 1 diabetes are emerging from the forefront of stem cell and islet cell biology. Basic research in animal models has uncovered a variety of mechanisms by which natural regeneration of pancreatic islet cells occurs, despite the underlying autoimmune defect. Two mechanisms - in particular, beta-islet cell proliferation and stem cell differentiation - can be harnessed in innovative ways in order to regenerate islets lost to disease. This review provides a background on stem cells and describes a range of potential biological therapies for type 1 diabetes, including the use of adult stem cells from the spleen, an organ not previously considered a source of pancreatic stem cells. Stem cells of the spleen have been demonstrated to home to the pancreas, where they mature into fully functional islet cells responsible for restoring normoglycemia. If the underlying autoimmune defect can be eradicated, stem cells of the spleen, as well as related strategies, can be used in order to regrow islets destroyed by type 1 diabetes.

Neural stem cells

Neural stem cells (NSCs) have the ability to self-renew, and are capable of differentiating into neurones, astrocytes and oligodendrocytes. Such cells have been isolated from the developing brain and more recently from the adult central nervous system. This review aims to provide an overview of the current research in this evolving area. There is now increasing knowledge of the factors controlling the division and differentiation of NSCs during normal brain development. In addition, the cues for differentiation in vitro, and the possibility of transdifferentiation are reviewed. The discovery of these cells in the adult brain has encouraged research into their role during neurogenesis in the normal mature brain and after injury. Lastly other sources of neural precursors are discussed, and the potential for stem cells to be used in cell replacement therapy for brain injury or degenerative brain diseases with a particular emphasis on cerebral ischaemia and Parkinson's disease.

Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo

The mechanisms controlling neural stem cell proliferation are poorly understood. Here we demonstrate that the PTEN tumor suppressor plays an important role in regulating neural stem/progenitor cells in vivo and in vitro. Mice lacking PTEN exhibited enlarged, histoarchitecturally abnormal brains, which resulted from increased cell proliferation, decreased cell death, and enlarged cell size. Neurosphere cultures revealed a greater proliferation capacity for tripotent Pten-/- central nervous system stem/progenitor cells, which can be attributed, at least in part, to a shortened cell cycle. However, cell fate commitments of the progenitors were largely undisturbed. Our results suggest that PTEN negatively regulates neural stem cell proliferation.

Neuronal potential and lineage determination by neural stem cells

How do neural stem cells ensure that they give rise to the right number and type of neurons at the right time? Over the past year several regulatory mechanisms have been identified, including promotion of neurogenesis by proneural bHLH genes, instruction of gliogenesis by Notch, and cell-intrinsic changes in the neurogenic capacity of stem cells in culture and in vivo.